Situated between the NDA and the ANDA is an increasingly popular drug commercialization pathway – the 505(b)(2) – and it potentially offers pharmaceutical companies clear advantages. We’ve been working with clients for years on 505(b)(2) drugs. At present, we are working on well over 100 API projects using the 505(b)(2) pathway. But why is there[…]
- Home
- About Us
- Products
- All Products
- Therapeutic Classifications
- Anti-Asthma / COPD
- Anti-Cancer / Oncology
- Anticonvulsants (Anti-Epileptics)
- Antihistamine
- Anti-Diabetic
- Antibiotics
- Anti-Emetics
- Anti-Hyperlipidemics
- Anti-Hypertensives
- Anti-Fungals
- Anti-Migraines
- Anti-Parkinsons
- Antiretroviral / Anti-HIV
- Anti-Thrombotics
- Contrast Agents
- Erectile Dysfunction (ED)
- Immunosuppressants
- Monoclonal Antibodies (mAbs)
- Oligonucleotides
- Prostaglandins
- Synthetic Peptides
- Research & Development (Preclinical Lab APIs)
- Clinical Phase API Supplies
- Commercial Stage cGMP APIs
- OTC Ingredients
- Pharmacy Compounding
- APIs for Drug Delivery Systems
- Services
- News
- Contact
- Search Products